Thyrocare Technologies Limited has informed the Exchange about the Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer of the Company w.e.f. January 05, 2026.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare Technologies has appointed Mr. Rajdeep Panwar as its Chief Commercial Officer, effective January 5, 2026. He is classified as Senior Management Personnel, and the appointment was approved by the Board on the recommendation of the Nomination and Remuneration Committee. Mr. Panwar brings over 21 years of experience in the healthcare and diagnostics sector, with prior leadership roles at Medanta Labs, Apollo Diagnostics, Dr. Lal PathLabs, Quest Diagnostics India, and Ortho Clinical Diagnostics (Johnson & Johnson). His expertise spans P&L management, laboratory network expansion, NABL/CAP accreditation, and scaling diagnostic operations across India.
This is a senior management-level appointment that strengthens Thyrocare's commercial leadership. For shareholders, it signals a focus on scaling diagnostic operations and commercial growth, though the immediate stock price impact is likely limited as it is not a board-level or CEO change.